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Abstract
In severe traumatic brain injury (TBI), contusions often are worsened by contusion expansion or hemorrhagic progression of
contusion (HPC), which may double the original contusion volume and worsen outcome. In humans and rodents with contusion-
TBI, sulfonylurea receptor 1 (SUR1) is upregulated in microvessels and astrocytes, and in rodent models, blockade of SUR1
with glibenclamide reduces HPC. SUR1 does not function by itself, but must co-assemble with either KIR6.2 or transient
receptor potential cation channel subfamily M member 4 (TRPM4) to form KATP (SUR1-KIR6.2) or SUR1-TRPM4 channels,
with the two having opposite effects on membrane potential. Both KIR6.2 and TRPM4 are reportedly upregulated in TBI,
especially in astrocytes, but the identity and function of SUR1-regulated channels post-TBI is unknown. Here, we analyzed
human and rat brain tissues after contusion-TBI to characterize SUR1, TRPM4, and KIR6.2 expression, and in the rat model, to
examine the effects on HPC of inhibiting expression of the three subunits using intravenous antisense oligodeoxynucleotides
(AS-ODN). Glial fibrillary acidic protein (GFAP) immunoreactivity was used to operationally define core versus penumbral
tissues. In humans and rats, GFAP-negative core tissues contained microvessels that expressed SUR1 and TRPM4, whereas
GFAP-positive penumbral tissues contained astrocytes that expressed all three subunits. Förster resonance energy transfer
imaging demonstrated SUR1-TRPM4 heteromers in endothelium, and SUR1-TRPM4 and SUR1-KIR6.2 heteromers in as-
trocytes. In rats, glibenclamide as well as AS-ODN targeting SUR1 and TRPM4, but not KIR6.2, reduced HPC at 24 h post-TBI.
Our findings demonstrate upregulation of SUR1-TRPM4 and KATP after contusion-TBI, identify SUR1-TRPM4 as the primary
molecular mechanism that accounts for HPC, and indicate that SUR1-TRPM4 is a crucial target of glibenclamide.
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Introduction
The most common mass lesions associated with traumaticbrain injury (TBI) are hemorrhagic brain contusions (BCs),
also called traumatic intracerebral hematomas, which occur in 13–
35% of patients following moderate-to-severe TBI.1–3 BCs remain
a serious clinical problem because of their associated morbidity.
Mechanical loading (i.e., applied mechanical forces) physically
destroy brain tissues and trigger mechanosensitive processes that
initiate secondary injury cascades in the surrounding penumbra,
most importantly, contusion expansion, or ‘‘hemorrhagic progres-
sion of contusion’’ (HPC). HPC is not simply an intracerebral he-
matoma that expands from a point source, compressing normal
brain, but instead is characterized by a progressive increase in the
volume of brain undergoing hemorrhagic transformation.4,5
HPC occurs during the first few hours after trauma, and the
pericontusional zone or ‘‘penumbra’’ is a key driver of this pro-
gression. An expanding hemorrhage post-TBI may be linked to
coagulopathy or platelet dysfunction,6 but absent these causes,
HPC is attributed to the catastrophic structural failure of micro-
vessels.4,5 Dysfunction or death of microvascular endothelial
cells in the penumbra results in the fragmentation of microvessels,
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leading to the formation of petechial hemorrhages.7 Experimental
work has shown that, as microvascular fragmentation progresses
outward from the initial site of contusion, petechial hemorrhages
coalesce, eventually doubling the original contusion volume over
the course of 12 h after trauma.4 In humans with BCs, HPC occurs
in 50–75% of cases, hemorrhagic lesion volumes expand 50% or
more with an average expansion rate of 0.7 mL per hour, and
increased expansion rates are significantly associated with poor
outcome or death.3,8,9
HPC is of vital clinical importance. HPC not only destroys brain
tissue, but it also causes brain swelling, the strongest prognostic
indicator of poor outcome in TBI.10,11 In TBI, brain swelling arises
from the combined space-occupying effects of extracellular edema
fluid, cellular swelling, extravasated blood, and other processes.
Edema, which is recognized as a major contributor to brain swelling,
can be treated using osmotherapeutic agents such as mannitol and
hypertonic saline. By contrast, extravasated blood, which arises from
both the initial contusion and from HPC, and which also is a major
contributor to brain swelling, currently has no clinical treatment.
Reducing HPC could significantly impact brain swelling in BC.
The ion channel regulatory subunit, sulfonylurea receptor 1
(SUR1), is strongly linked to TBI, especially BC. SUR1 protein and
Abcc8 messenger RNA (mRNA), which encodes SUR1, are tran-
scriptionally upregulated at the site of injury in animal models of
TBI and in humans with TBI.4,12,13 SUR1 upregulation is found in
microvascular endothelium, astrocytes, and neurons. SUR1 is held
to be responsible for microvascular failure leading to edema and
HPC, since edema, capillary fragmentation and HPC are reduced
by blocking SUR1 with glibenclamide.4,14–17 In a recent study in
humans, Jha and colleagues showed that the level of SUR1 in the
ventricular cerebrospinal fluid was a good biomarker of brain
swelling identified on the computed tomography (CT) scan.18 Also,
the same group showed that ABCC8 genetic variability in patients
with TBI and regionally clustered single nucleotide polymorphisms
are associated with post-traumatic brain swelling.19,20 Recently,
pharmacological inhibition of SUR1 was shown in human clinical
trials to reduce brain swelling after ischemic stroke21 and to reduce
HPC after TBI.22
The unique molecular biology of SUR1 has hindered a full un-
derstanding of its pathological role in TBI. SUR1 is a member of
the adenosine triphosphate (ATP) binding cassette (ABC) trans-
porter superfamily. SUR1 does not function by itself but instead
modulates the properties of distinct pore-forming ion channels
by participating in heterologous co-associations. In different
cell types, SUR1 co-assembles either with the inwardly rectifying
K+ (KIR) 6.2 channel to form KATP channels,
23–25 or with transient
receptor potential melastatin 4 (TRPM4) to form SUR1-TRPM4
channels.26 Notably, these two channels have opposite physiolog-
ical effects—upon activation, KATP channels mediate K
+ efflux and
cell hyperpolarization, whereas SUR1-TRPM4 channels mediate
Na+ influx and cell depolarization. In TBI, little is known about
SUR1’s potential pore-forming subunit partners. Two recent re-
ports have shed important light on this question, but these reports
yielded unexpected findings: Gorse and colleagues27 reported that
TRPM4 was upregulated in a rodent model of TBI, especially in
astrocytes, whereas Castro and colleagues28 reported that KIR6.2
was upregulated in humans with TBI, again especially in astro-
cytes. Given the opposite functional effects of the two channels, we
thought it important to revisit this question of astrocyte expression
of SUR1-regulated channels post-TBI. Also, given the critical role
of SUR1 in HPC post-TBI, we thought it important to determine
which of the SUR1-regulated channels was linked to HPC.
Here, we studied the expression and assembly of SUR1, TRPM4
and KIR6.2 in brain tissues from humans with TBI and from a rat
model of TBI, with a particular focus on astrocyte expression of
these channels. To address the function of the three subunits in
HPC, we studied the effects of antisense-mediated gene knock-
down of the three subunits in a rat model of contusion-TBI. Here,
we report that, indeed, both TRPM4 and KIR6.2 are upregulated
post-TBI in astrocytes of both species, where they co-assemble
with SUR1 to form heteromers of SUR1-TRPM4 and SUR1-
KIR6.2. Also, we report that inhibiting the expression of SUR1 and
TRPM4, but not KIR6.2, reduces HPC post-TBI.
Methods
Human tissues
All cases were patients at the R. Adams Cowley Shock Trauma
Center, Baltimore; the cases reported here are distinct from the
cohort from Barcelona reported earlier.13,28 The tissue collection
protocol was approved by the Institutional Review Board (IRB) of
the University of Maryland School of Medicine. Under this IRB
protocol, brain tissue biopsy specimens were obtained from 16
patients with non-ballistic, closed head injury, contusion-TBI who
underwent decompressive craniectomy (by BA or JMS) for ele-
vated intracranial pressure29 between January 12, 2013, and August
3, 2014. All had CT scans exhibiting hemorrhagic contusions with
mass effect. Patients were (mean – standard deviation) 48 – 20
years of age, and 81% were male. The mechanism of injury was
motor vehicle accident, pedestrian struck, or assault. Time to sur-
gery was 58 – 85 h (range, 2–280) after TBI.
In each case, one or two biopsy specimens, 0.5–1 cm3, were
obtained from what appeared grossly to be non-necrotic brain at the
interface between contused brain and normal-appearing brain.
Following biopsy, specimens were placed immediately in 4%
formaldehyde for immersion fixation. Tissues were cryoprotected
with 30% sucrose, embedded in optimum cutting temperature
(OCT) compound, frozen on dry ice, and cryosectioned (10 lm).
For control tissues, five postmortem specimens were obtained
from three men and two women who died rapidly from non-
neurological diseases, including pneumonia, status asthmaticus,
and rupture of aortic aneurysm.30 The postmortem interval ranged
from 18–74 h. The average age of control subjects was 51.3 – 7.0
years.
Antibody validation
The custom anti-SUR1 and anti-TRPM4 antibodies used for
immunolabeling and immunoFRET in this study were validated
previously using lysates from appropriate SUR1 and TRPM4 ex-
pression systems, tissues from wild-type, Trpm4–/– and Abcc8–/–
mice, and using mass spectrometry of immunoisolated pro-
teins,26 in accordance with recommendations for antibody val-
idation by Uhlen and colleagues.31 Here, we further validated
the specificity of the custom anti-SUR1 antibody for immuno-
histochemistry of human tissues by comparing immunolabeling
of adjacent sections using our custom polyclonal antibody, a
monoclonal antibody (S289-16; Novus Biologicals, Littleton,
CO) and a commercial polyclonal antibody (sc-5789; Santa Cruz
Biotechnology, Dallas, TX).
We evaluated the suitability of three commercial anti-KIR6.2
antibodies using myc-tagged KIR6.x (myc-KIR6.2 or myc-KIR6.1)
plasmids expressed in COS-7 cells. Myc-KIR6.2 and myc-KIR6.1
plasmids were constructed as follows. Complementary DNA clones
encoding mouse Kcnj11 (KIR6.2) and Kcnj8 (KIR6.1) were ob-
tained from Dr. Shyng (Oregon Health and Science University,
Portland, OR) and DNASU Plasmid Repository (Tempe, AZ), re-
spectively, and used as templates for polymerase chain reaction
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(PCR). The amplified PCR products were cloned into pCMV-
Tag3C vector (Agilent Technologies, Santa Clara, CA) for ex-
pression of myc-KIR6.x. The myc-KIR6.x plasmids were verified
by DNA sequencing prior to transfection.
Whole–cell lysates and myc-KIR6.2 immunoprecipitates were
immunoblotted using anti-myc antibody (sc-40; Santa Cruz Bio-
technology) or one of three anti-KIR6.2 antibodies: 1) GTX80493,
an anti-human (N-terminus of KIR6.2), rabbit polyclonal antibody
from GeneTex (Irvine, CA); 2) sc-11226, an anti-human (N-
terminus of KIR6.2) goat polyclonal antibody from Santa Cruz
Biotechnology; or 3) sc-11228, an anti-human (internal region of
KIR6.2) goat polyclonal antibody from Santa Cruz Biotechnology.
Anti-myc immunoblot of whole–cell lysates and of myc-KIR6.2
immunoprecipitate from cells transfected with empty vector yiel-
ded no bands (Fig. 1A; lanes 1, 3). Anti-myc immunoblots of
whole–cell lysates and myc-KIR6.2 immunoprecipitate from cells
transfected with myc-KIR6.2 showed bands at *75 kDa, *110 kDa,
and *150 kDa (Fig. 1A; lanes 2, 4). An additional band at *38 kDa
was observed in the anti-myc immunoblot of myc-KIR6.2 im-
munoprecipiate (Fig. 1A; lane 4). These four bands correspond to
the monomer and multimers of KIR6.2.32
The antibody from GeneTex yielded an immunoblot that was
nearly identical to that obtained with anti-myc antibody (Fig. 1A;
lanes 5–8). GTX80493 detected all multimers of KIR6.2 (Fig. 1A;
lane 8). GTX80493 showed one faint nonspecific band *120 kDa
in the absence of KIR6.2 expression (Fig. 1A; lane 5).
The antibodies from Santa Cruz Biotechnology were evaluated
using only whole–cell lysates (Fig. 1B; lanes 1, 2). When used to
immunoblot lysates that did not contain KIR6.2, the sc-11228
immunoblot showed many nonspecific bands (Fig. 1B; lane 3), and
detected KIR6.2 only very poorly (Fig. 1B; lane 4). Similarly, sc-
11226 showed many nonspecific bands (Fig. 1B; lane 5), although
it did detect all KIR6.2 multimers (Fig. 1B; lane 6).
We also evaluated the ability of GTX80493 to distinguish be-
tween KIR6.2 and KIR6.1 (both of which can be expressed by
astrocytes; see Discussion). COS7 cells were used to express myc-
KIR6.2 or myc-KIR6.1, as above. Immunoblot using anti-myc
antibody confirmed the expression of both (Fig. 1C). Immunoblot
using GTX80493 again confirmed detection of KIR6.2 multimers,
but KIR6.1 was not detected. As noted above, GTX80493 showed
one faint nonspecific band *120 kDa in both the absence and
presence of KIR6.x expression (Fig. 1C).
To further validate GTX80493 specifically for immunohisto-
chemistry, we used it to co-localized expression of KIR6.2 protein
and Kcnj11 mRNA in brain tissue sections from contusion-TBI
patients. In situ hybridization was performed for Kcnj11 mRNA,
and the same tissue section was double-immunolabeled for glial
fibrillary acidic protein (GFAP) and for KIR6.2 using GTX80493
(see Methods). Immunolabeling showed GFAP-expressing stellate
cells with prominent expression of KIR6.2, with the same cells also
exhibiting Kcnj11 mRNA (Fig. 1D; asterisks). In the same field,
other cells were present, as identified by nuclear staining with 4¢,6-
diamidino-2-phenylindole (DAPI); these cells showed no immu-
noreactivity with GTX80493, and no Kcnj11 mRNA (Fig. 1D;
circles). Using a different anti-KIR6.2 antibody (APC-020; Alomone
Labs) that was validated previously28 confirmed astrocyte-specific
expression of KIR6.2 in the same tissue specimen (Fig. 1E).
GTX80493 exhibited no immunoreactivity when used to label
control (uninjured) GFAP+ tissues (Fig. 1F).
All immunohistochemistry for KIR6.2 reported in this manu-
script was conducted using GTX80493.
Histology, immunolabeling, and immunoFRET
of human tissues
Human sections were stained with hematoxylin and eosin using
routine techniques, and were examined with light microscopy. For
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay, cryosections were processed according to kit in-
structions (C10617; Thermo Fisher Scientific Inc.).
For fluorescence immunohistochemistry, cryosections were
blocked 1 h in 2% donkey serum (D9663; Sigma-Aldrich, St. Louis,
MO) and 0.2% Triton X-100. After rinsing, sections were incubated
overnight at 4C with a primary antibody: goat ant-SUR1 (1:500;
custom antibody,26 mouse monoclonal anti-SUR1 (1:100; S289-
16; Novus Biologicals), goat anti-SUR1 (C-16; 1:200; sc-5789;
Santa Cruz Biotechnology, Santa Cruz, CA), chicken anti-TRPM4
(1:500; custom antibody), goat anti-TRPM4 (G-20; 1:200; sc-
27540; Santa Cruz Biotechnology), or KIR6.2 (1:100; GTX80493;
GeneTex, Irvine, CA). After labeling for one of the channel
subunits, double immunolabeling was performed using either:
CY3-conjugated, monoclonal anti-GFAP (1:500; C9205; Sigma-
Aldrich), or rabbit anti-collagen IV (1:200; ab6586; Abcam,
Cambridge, MA), or mouse anti-CD68 (ED1; 1:100; MAB1435;
‰
FIG. 1. KIR6.2 antibody validation. (A) Whole–cell lysate (WL) or anti-myc immunoprecipitate (IP) were prepared from COS-7 cells
transfected with myc-KIR6.2 or empty vector; immunoblot with anti-myc antibody showed no bands with expression of empty vector
(lanes 1, 3), and showed KIR6.2 monomers and multimers with KIR6.2 expression (lanes 2, 4); immunoblot with GTX80493 anti-
KIR6.2 antibody showed a single faint nonspecific band in WL immunoblot of empty vector (lane 5), and showed KIR6.2 monomers
and multimers with KIR6.2 expression (lanes 6, 8); representative of three experiments. (B) Whole lysate was prepared from COS-7
cells transfected with myc-KIR6.2 or empty vector; immunoblot with anti-myc antibody showed no bands with expression of empty
vector (lane 1), and showed KIR6.2 monomers and multimers with KIR6.2 expression (lane 2); immunoblot with sc-11228 anti-KIR6.2
antibody showed multiple nonspecific bands with expression of empty vector (lane 3), and no KIR6.2 with expression of KIR6.2 (lane
4); immunoblot with sc-11226 anti-KIR6.2 antibody showed multiple nonspecific bands with expression of empty vector (lane 5), and
showed KIR6.2 multimers with expression of KIR6.2 (lane 6); representative of three experiments. (C) Whole lysate was prepared from
COS-7 cells transfected with empty vector, or myc-KIR6.1 or myc-KIR6.2; immunoblot with anti-myc antibody showed no bands with
expression of empty vector, and showed KIR6.1 or KIR6.2 multimers with KIR6.1 or KIR6.2 expression, as indicated; immunoblot with
GTX80493 anti-KIR6.2 antibody showed a single faint nonspecific band with empty vector and with KIR6.1 expression, and showed
multimers with KIR6.2 expression, as indicated; representative of three experiments. (D) Combined in situ hybridization and double
immunolabeling of the same tissue section from human brain after TBI. Upper panel: superimposed double immunolabeling for KIR6.2
(GTX80493, GeneTex; green) and glial fibrillary acidic protein (GFAP; red) showed astrocytes that express KIR6.2 (asterisks); in the
same field, other cells identified by 4¢,6-diamidino-2-phenylindole staining of nuclei showed no immunoreactivity for GFAP or KIR6.2
(red circles). Lower panel: in situ hybridization for Kcnj11 in the same tissue section showed positive signal within the same astrocytes
that express KIR6.2 protein (asterisks), and no signal in cells that express no KIR6.2 protein (circles); representative of five experiments.
(E) Double immunolabeling for KIR6.2 using APC-020 (Alomone Labs; green) and GFAP (red) in tissues from the same case as in (D)
confirmed the specificity of the anti-KIR6.2 antibody, GTX80493. (F) Double immunolabeling for KIR6.2 (GTX80493, GeneTex;
green; green) and GFAP (red) in control (uninjured) cortical tissue showed that GTX80493 exhibited no immunoreactivity when used to
label control GFAP+ tissues.
1062 GERZANICH ET AL.
Millipore Sigma, Burlington, MA), to analyze cell-specific ex-
pression. For visualization, we used fluorescent-labeled species-
appropriate secondary antibodies (1:500, Alexa Fluor 488 [green]
and Alexa Fluor 555 [red]; Invitrogen/Molecular Probes, Eugene,
OR) at room temperature. Sections were cover-slipped using Pro-
Long Gold antifade reagent containing the nuclear stain, DAPI
(Invitrogen). Immunolabeled sections were visualized using epi-
fluorescence microscopy (Nikon Eclipse 90i; Nikon Instruments
Inc., Melville, NY). Specific labeling was defined as fluorescence
intensity twice that of background. Controls included incubation
with pre-immune serum, when available, omission of primary
antibodies, and testing cell-specific antibodies (anti-GFAP, anti-
CD68) to assure no cross-reactivity with SUR1, TRPM4, or
KIR6.2.
To demonstrate formation of SUR1-TRPM4 and SUR1-KIR6.2
heteromers, we performed antibody-based Förster Resonance En-
ergy Transfer (immunoFRET),33 using methods we described.26,34,35
To study SUR1-TRPM4 heteromers, we used rabbit anti-SUR1
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(1:200; custom antibody) and goat anti-TRPM4 (G-20; 1:200; sc-
27540; Santa Cruz Biotechnology) primary antibodies, along with
donkey anti-rabbit CY5 (1:100) and mouse anti-goat CY3 (1:100)
(the Jackson Laboratory) secondary antibodies. To study SUR1-
KIR6.2 heteromers, we used goat anti-SUR1 (1:400; custom
antibody) and rabbit anti-KIR6.2 (1:50: GTX80493; Genetex)
primary antibodies, along with donkey anti-rabbit CY5 (1:100)
and mouse anti-goat CY3 (1:100; the Jackson Laboratory) sec-
ondary antibodies. Sections were first immunolabeled using a
mixture of the two primary antibodies, with incubation performed
overnight at 4C. After washing with phosphate-buffered saline
(PBS), the sections were incubated with a mixture of the two
secondary antibodies for 1 h, rinsed and cover-slipped. FRET
fluorescence imaging was analyzed on a commercial laser scan-
ning microscope combination system, LSM510 Meta (Zeiss, Jena,
Germany) with an Axiovert inverted microscope and a 63 · oil
immersion lens. The following settings were used throughout the
experiments: for Cy3, excitation, 543 nm; detection, 565–615 nm;
for Cy5, excitation, 633 nm; detection, 650–704 nm. The images
were captured and processed with the LSM Image Examiner
software (Zeiss), with an integration time of 5 msec/pixel. ROIs
were three rectangles, 225 · 180 lm, positioned within GFAP+
tissues. Controls studied here included omission of primary an-
tibodies and study of uninjured control brain tissues; additional
controls for immunoFRET validation used a COS-7 cell expres-
sion system, as described.26
Immunohistochemistry analysis
Channel subunit expression was assessed in all cases, but was
quantified only in cases with GFAP-positive specimens. Unbiased
measurements of signal intensity within regions of interest (ROIs)
were obtained using NIS-Elements AR software (Nikon Instru-
ments, Melville, NY). Images were collected from sections dou-
ble immunolabeled for GFAP and SUR1 or TRPM4 or KIR6.2.
The GFAP channel was used to define ROIs (pixel intensity
>2 · background). The GFAP-defined ROIs were used to quantify
astrocyte-specific expression of SUR1, TRPM4, or KIR6.2, with
the % ROI calculated by dividing the number of positive pixels (>
2 · background) for individual channel subunits by the total number
of GFAP+ pixels in the ROI. For each case, three representative
areas (410 · 325 lm ROI) were analyzed and averaged.
In situ hybridization
For in situ hybridization, cryosections were processed with
digoxigenin-labeled probes against Abcc8 (antisense: 5¢-TGCA
GGGGTCAGGGTCAGGGCGCTGTCGGTCCACTTGGCCAG
CCAGTA-3¢), TRPM4 (antisense: 5¢-CCGAGAGTGGAATTCCC
GGATGAGGCGGTAACGCTGC-3¢), or KIR6.2 (antisense: 5¢-CCA
TGCGCCCCCCAAAGCCAATAGTCACTTGGACCTCAAT-3¢),
supplied by IDT (Skokie, IL). In situ hybridization was performed
on 10-lm sections and controls using an IsHyb In Situ Hybridiza-
tion (ISH) Kit (Biochain Institute, Inc., Newark, CA) according to
the manufacturer’s protocol. Sections were incubated in diethyl
pyrocarbonate (DEPC)–treated PBS and fixed in 4% paraformal-
dehyde in PBS for 20 min. After being rinsed twice with DEPC-
PBS, the slides were treated with 10 lg/mL proteinase K at 37C for
10 min. Slides were then washed in DEPC-PBS, rinsed with DEPC-
H2O, and prehybridized with ready-to-use prehybridization solution
(BioChain Institute, Newark, CA) for 3 h at 50C. The DIG-labeled
probe was diluted in hybridization buffer (BioChain Institute,
Newark, CA) and applied at 4 ng/lL. Sections then were incubated
at 45C for 16 h. Post-hybridization washing and immunological
detection, using anti-DIG-alkaline phosphatase (AP) with NBT/
BCIP as substrates were performed as recommended by the man-
ufacturer. AP-conjugated anti-DIG antibodies (1:100 PBS diluted,
BioChain Institute, Newark, CA), were incubated with slides for 2 h.
Finally, slides were rinsed in distilled H2O and then were im-
munolabeled for the corresponding protein using a fluorescent
secondary antibody, as above.
Rat experiments
Ethics statement. We certify that all applicable institutional
and governmental regulations concerning the ethical use of animals
were followed during the course of this research. Animal exper-
iments were performed under a protocol approved by the Institu-
tional Animal Care and Use Committee of the University of
Maryland School of Medicine, and in accordance with the relevant
guidelines and regulations as stipulated in the United States Na-
tional Institutes of Health Guide for the Care and Use of Laboratory
Animals. All efforts were made to minimize the number of animals
used and their suffering.
Subjects and surgical procedure for contusion-TBI. Male
Wistar rats, ages 12–16 weeks (325–400 g; Harlan, Indianapolis,
IN), were anesthetized (60 mg/kg ketamine plus 7.5 mg/kg xyla-
zine, intraperitoneally) and allowed to breathe room air spontane-
ously. Core temperature was maintained at 37C with an isothermal
pad (Deltaphase; Braintree Scientific, Braintree, MA). Oxygen
saturation and heart rate were monitored using a pulse oximeter
(Mouse Ox; STARR Life Sciences Corp., Oakmont, PA). Sur-
gical incision sites were prepared using iodine and alcohol, and a
sterile environment was maintained throughout the procedure. Rats
were mounted in a stereotactic apparatus (Stoelting Co., Wood
Dale, IL). Lidocaine solution (2%) was injected prior to making an
incision. A midline scalp incision was made to expose the skull. A
circular bone incision positioned 2 mm anterior to lambda and
1 mm lateral to midline was made using a high-speed drill with a
1 mm diamond burr (Dremel, model 732), to create a 6-mm di-
ameter craniotomy in the left parietal region. After removing the
bone flap, contusion-TBI was induced using a controlled cortical
impact device (Impact One impactor system; 39463920; Leica
Biosystems, Buffalo Grove, IL) with the following parameter set-
tings: 5 mm diameter impactor, angled 20 from vertical, 4.5 mm
tissue displacement from the dural surface, 1 m/sec velocity, 200 msec
dwell time. The bone flap was then repositioned and cemented in
place using a cyanoacrylate adhesive (Loctite 454 Prism Instant
Adhesive Gel plus Insta-Set accelerator). For analgesia, we used
buprenorphine (0.05 mg/kg) 15 min before surgery then every
12 h for 24 h.
Series. Four series of rats with contusion-TBI were studied. In
series 1, five contusion-TBI rats were euthanized at each of four
time-points: 6, 12, 24 and 72 h, with five uninjured rats serving as
controls; these rats were used for immunohistochemistry. In series
2, five contusion-TBI rats received no treatment and were eutha-
nized at 15 min to measure the hemorrhagic lesion area (primary
hemorrhage before HPC) and hemispheric swelling. In series 3, 18
contusion-TBI rats were administered either glibenclamide (nine
rats) or vehicle (nine rats). In series 4, 53 contusion-TBI rats were
administered either antisense-oligodeoxynucleotide (AS-ODN)
targeting a channel subunit, or scrambled ODN (Scr-ODN) or sense
ODN (SE-ODN) as control, including AS-ODN targeting SUR1
(12 rats, with 10 Scr-ODN controls), TRPM4 (seven rats, with eight
SE-ODN controls) or KIR6.2 (eight rats, with eight SE-ODN
controls). Rats in series 3 and series 4, were euthanized at 24 h to
measure the hemorrhagic lesion area (primary hemorrhage plus
secondary hemorrhage after HPC) and hemispheric swelling.
Treatments. The drug formulation for glibenclamide (#G2539;
Sigma) in dimethyl sulfoxide was as described.36 Treatment consisted
of administering a single loading dose of glibenclamide (10 lg/kg) or
an equivalent volume of vehicle intraperitoneally within 10 min of
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trauma, as well as continuous infusion via mini-osmotic pump (Alzet
2001, 1.0 lL/h; Alzet Corp, Cupertino, CA) beginning at the end of
surgery, resulting in delivery of 400 ng/h or an equivalent volume of
vehicle subcutaneously until euthanasia. The dose of glibenclamide
used here has been shown to not result in hypoglycemia.
Anti-SUR1 (5¢-GGCCGAGTGGTTCTCGGT-3¢) and anti-
TRPM4 (5’-TTGTGGTAACACTCTCCAAA-3¢) AS-ODNs were
described and validated previously in rats in vivo.37–39 These AS-
ODNs were shown to result in >60% suppression of protein ex-
pression as well as highly significant reductions in progressive
hemorrhagic necrosis in a contusion spinal cord injury model. Anti-
KIR6.2 (5¢-CCTTTCGGGACAGCATGGCT-3¢) AS-ODN was
described and validated previously in rats in vivo.40 This AS-ODN
was shown to result in 80% suppression of Kcnj11 mRNA expression
in the basal ganglia. ODNs, which were phosphorothioated at 4 distal
bonds at both the 5¢ and 3¢ ends to protect against endogenous nu-
cleases,41 were obtained commercially (Sigma-Aldrich). Prior to
surgery, mini-osmotic pumps (Alzet 2001D, 8 lL/h; Durect Corp.)
fitted with jugular vein catheters were loaded with ODN and primed.
ODN solutions were prepared in sterile normal saline (NS; 4 mg/mL).
Immediately after trauma, the jugular vein was catheterized, a
loading dose of ODN (400 lg in 100 lL) was administered intra-
venously, and the pump catheter was inserted into the vein with
the pump implanted subcutaneously in the dorsal thorax, to obtain
intravenous delivery of ODN at a rate of 32 lg /h until euthanasia,
yielding a total dose delivered of *1.2 mg/24 h.
Exclusions. In all series, there was no unplanned mortality,
and no animal was excluded for any reason.
Hemorrhagic lesion area and hemispheric swelling
At the designated time after trauma, rats were euthanized by an
intraperitoneal injection of pentobarbital (> 100 mg/kg), then un-
derwent transcardial perfusion with NS (60 mL) followed by 10%
neutral buffered formalin (50 mL; Sigma-Aldrich). Immediately
after perfusion-fixation, brains were harvested and bisected cor-
onally at the contusion epicenter using a pre-chilled (-20C) rat
brain coronal matrix (Ted Pella Inc., Redding, CA). The exposed
coronal faces were imaged on a flatbed scanner to obtain high
resolution digital images (red-green-blue [RGB]; 600 dpi).
To obtain unbiased measurements of hemorrhagic lesion area,
we used an algorithm-based segmentation protocol similar to what
we used previously for TTC-stained sections after ischemia,42
taking into account that the colors red and white have opposite
biological meaning in the two scenarios. NIS-Elements AR soft-
ware (Nikon Instruments, Melville, NY) was used to process the
RGB images. The quadrant that included cortex, corpus callosum
and hippocampus with normal-appearing brain surrounding the
contusion was outlined manually. The hemorrhagic lesion area
within this quadrant was determined, based on pixel intensities
identified by a histogram of the green channel (dark pixels depict
blood; brighter pixels depict normal brain). The percent hemor-
rhagic lesion was calculated based on the hemorrhagic lesion area
and the area of the manually traced ipsilateral hemisphere. The
percent hemispheric swelling was calculated based on the areas of
the manually traced ipsilateral and contralateral hemispheres. This
unbiased method of segmentation for determining the hemorrhagic
lesion area was validated in a subset of images by two investigators
(ZI, JAS), blinded to treatment group, who independently traced the
hemorrhagic area manually on full color RGB images. HPC is
defined as the increase in hemorrhagic lesion area at 24 h compared
with 15 min after trauma.
Immunolabeling and TUNEL staining of rat tissues
For rat tissues, cryosections were immunolabeled as above using
the following primary antibodies: goat ant-SUR1 (1:500; custom
antibody),26 chicken anti-TRPM4 (1:500; custom antibody), goat
anti-TRPM4 (G-20; 1:200; sc-27540; Santa Cruz Biotechnology),
or KIR6.2 (1:100; GTX80493; GeneTex, Irvine, CA). After la-
beling for one of the channel subunits, double immunolabeling was
performed using either: CY3-conjugated, monoclonal anti-GFAP
(1:500; C9205; Sigma-Aldrich), or monoclonal anti-RECA
(MA1-81510; 1:100; HIS52; Invitrogen, ThermoFisher Scientific,
Waltham, MA), or mouse anti-CD68 (ED1; 1:100; MAB1435;
Millipore Sigma), to analyze cell specific expression. Secondary
antibodies and subsequent image processing, as well as TUNEL
labeling were performed as above.
Statistical analysis
Data are presented as mean – SEM, unless otherwise noted. The
treatment effect (percent reduction in hemorrhagic lesion area or
percent reduction in hemispheric swelling) was calculated as: (AV–
AD)/(AV-AB)*100, where AB is area at baseline, AV is area at 24 h
with vehicle/control treatment, and AD is area at 24 h with drug
treatment. Statistical analyses were performed using Origin Pro
(V8; OriginLab Corp, Northampton, MA). Student’s t-test and one-
way analysis of variance with Tukey’s honestly significant differ-
ence post hoc comparisons were used as appropriate.
Results
Brain tissue specimens from 16 patients with non-ballistic
contusion-TBI who required decompressive craniectomy were first
immunolabeled for GFAP. Since GFAP expression is reduced or
absent in the core of ischemic and contusion injuries,43–45 whereas
it is upregulated in surrounding penumbral regions, we used GFAP
immunoreactivity to operationally classify our specimens as being
GFAP-negative, likely from core regions, or GFAP-positive, likely
from penumbral regions. In eight cases, GFAP labeling was absent
or near-absent in all specimens, and in most of these, there was
widespread TUNEL labeling indicative of severe cellular damage,
consistent with these specimens originating from potentially non-
viable core regions. In the other eight cases, GFAP immunolabeling
was prominent in most of the specimens, with modest or no TUNEL
labeling, consistent with these specimens originating from or con-
taining viable penumbral tissues. In one of the GFAP-positive cases,
two specimens were obtained, with one specimen showing robust
GFAP immunoreactivity and the other specimen from the same
patient being GFAP-negative (Fig. 2), illustrating the dichotomous
nature of GFAP immunoreactivity in contusion specimens.
GFAP-negative human specimens
GFAP-negative specimens were immunolabeled for SUR1. Half
of the GFAP-negative specimens also were negative for SUR1. The
other GFAP-negative specimens showed prominent SUR1 ex-
pression, which was markedly greater compared with control tis-
sues (Fig. 3A). Structures that were immunopositive for SUR1
consisted of elongated structures, likely microvessels, as well as
small round cells (Fig. 3A).
Double immunolabeling for collagen IV, which identifies the
basal lamina of microvessels, and for SUR1 or TRPM4 or KIR6.2,
showed expression of SUR1 and TRPM4 in microvessels (Fig. 3B,
3C). Immunolabeling for CD68 showed that most of the small
round cells were microglia/macrophages. Double immunolabeling
for CD68 and SUR1 or TRPM4 or KIR6.2 showed expression of the
three channel subunits in microglia/macrophages (Fig. 3D-F).28
Double immunolabeling showed that SUR1 and TRPM4 were co-
localized in both microvessels and small round cells (Fig. 3G), and
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FRET imaging showed that SUR1 and TRPM4 co-assembled to
form SUR1-TRPM4 heteromers in microvessels (Fig. 3H).
GFAP-positive human specimens
GFAP-positive specimens were immunolabeled for SUR1. All
of the GFAP-positive specimens also were positive for SUR1, which
was markedly greater compared with control tissues (Fig. 4A), as
reported.13 The most prominent structures that were immunopositive
for SUR1 were stellate-shaped cells (Fig. 4A). Double immunolabeling
for SUR1 and GFAP or CD68 or collagen IV showed that SUR1
expression was by far more prominent in astrocytes and minimal
or absent in microvessels or microglia/macrophages (Fig. 4B).
SUR1 expression in occasional non-GFAP-positive cells, some
of which may have been neurons or microglia/macrophages,13
was not studied in these specimens.
GFAP-positive cells that expressed SUR1 protein also expressed
ABCC8 mRNA (Fig. 4B). Immunolabeling with two other anti-
SUR1 antibodies, a monoclonal (S289-16; Novus Biologicals) and
a commercial polyclonal (sc-5789; Santa Cruz Biotechnology),
yielded images similar to those obtained with the custom anti-
SUR1 antibody (Fig. 4C). Quantification using GFAP as the region
of interest confirmed that SUR1 was significantly upregulated in
penumbral astrocytes post-TBI (Fig. 4D).
Like SUR1, TRPM4 was minimally expressed in control cortical
tissues, but was upregulated in GFAP-positive penumbral speci-
mens (Fig. 5A), similar to that reported in diffuse TBI.27 Double
immunolabeling with GFAP showed that TRPM4 expression was
prominent in astrocytes, and could also be observed in small round
cells (Fig. 5B). GFAP-positive cells that expressed TRPM4 protein
also expressed TRPM4 mRNA, as did some small round cells
(Fig. 5B). Co-immunolabeling showed that astrocytes that labeled
positive for TRPM4 also labeled positive for SUR1 (Fig. 5C), and
FRET experiments showed that TRPM4 and SUR1 formed het-
eromers of SUR1-TRPM4 (Fig. 5D). Quantification using GFAP as
the region of interest confirmed that TRPM4 was significantly
upregulated in cortical astrocytes post-TBI (Fig. 4D).
Like SUR1 and TRPM4, KIR6.2 was minimally expressed in
control cortical tissues, except in occasional neurons, but was up-
regulated in GFAP-positive penumbral specimens (Fig. 6A), as
reported.28 Double immunolabeling with GFAP showed that
KIR6.2 expression was prominent in astrocytes (Fig. 6B). KIR6.2
expression in non-GFAP-positive cells, presumably neurons, was
sparse and did not differ appreciably from controls.28 GFAP-
positive cells that expressed KIR6.2 protein also expressed
KCNJ11 mRNA (Fig. 6B). Co-immunolabeling showed that cells
that labeled positive for KIR6.2 also labeled positive for SUR1
(Fig. 6C), and FRET experiments showed that KIR6.2 and SUR1
formed heteromers of SUR1-KIR6.2 (Fig. 6D). Quantification us-
ing GFAP as the region of interest confirmed that KIR6.2 was
significantly upregulated in cortical astrocytes post-TBI (Fig. 4D).
Double immunolabeling showed that TRPM4 and KIR6.2 were
expressed in the same cells whose stellate morphology was consistent
with astrocytes (Fig. 6E). Overall, qualitative assessment of the eight
GFAP-positive specimens revealed that the three subunits, SUR1,
TRPM4, and KIR6.2, tended to be upregulated in parallel in astrocytes,
that expression during the first 24 h after injury tended to be variable,
and that later, essentially all astrocytes upregulated all three subunits.
Channel subunit expression in rat contusion-TBI
In the rat contusion model, the lesion core identified by the
hemorrhagic area in unstained sections showed markedly reduced
GFAP immunoreactivity45 along with markedly elevated TUNEL
labeling (Fig. 7A, 7B), consistent with previous findings,43–45 and
consistent with our rational for dichotomizing the human specimens.
We studied SUR1 expression in the core and penumbra as a
function of time. In the core, SUR1 expression was significantly
increased over controls, it peaked at 6 h, remained elevated at 12 h,
declined at 24 h, then rose again at 72 h (Fig. 7C).4,12 During the
first 24 h, the primary structures within the core that labeled for
SUR1 were elongated structures, consistent with microvessels
(Fig. 7D). However, at 72 h, labeling of microvessels was no longer
evident and instead, labeling was most prominent in small round
FIG. 2. Glial fibrillary acidic protein (GFAP) immunoreactivity
dichotomizes human contusion–traumatic brain injury (TBI)
specimens. (A-C) Two sections from the same patient, stained
with hematoxylin and eosin (A) or immunolabeled for GFAP (B,
C), with the latter shown at low (B) and high (C) magnification:
Note absence of specific immunoreactivity for GFAP in the
specimen on the left vs. specific labeling of stellate-shaped cells in
the companion specimen on the right. (case #2, 11 days post-TBI).
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FIG. 3. (A) Immunolabeling for sulfonylurea receptor 1 (SUR1) showed sparse immunoreactivity in the control specimen (CTR) vs.
widespread expression in elongated structures and small round cells in a glial fibrillary acidic protein (GFAP)–negative specimen from
contusion–traumatic brain injury (TBI). (B, C) Double immunolabeling for collagen IV (COLIV) (red) and SUR1 (B) or transient
receptor potential cation channel subfamily M member 4 (TRPM4) (C) showed expression of SUR1 and TRPM4 in microvessels;
merged images are also shown. (D-F) Double immunolabeling for CD68 (red) and SUR1 (D) or TRPM4 (E) or KIR6.2 (F) showed
expression of SUR1, TRPM4 and KIR6.2 in microglia/macrophages; merged images are also shown. (G) Double immunolabeling for
SUR1 (green) and TRPM4 (red) showed co-localization in a microvessel. (H) ImmunoFRET for SUR1 (red) and TRPM4 (magenta)
shows co-assembly of SUR1-TRPM4 heteromers (yellow pseudocolor) in a microvessel. The findings illustrated are from the GFAP-
negative specimen shown in Figure 2, left, and are representative of all GFAP-negative, SUR1-positive specimens from four cases of
human contusion-TBI; (four cases with GFAP-negative specimens showed no immunoreactivity for SUR1). Case #2, 11 days post-TBI;
case #3, 7 days post-TBI.
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FIG. 4. Glial fibrillary acidic protein (GFAP)–positive specimens from human contusion– traumatic brain injury (TBI) exhibit
sulfonylurea receptor 1 (SUR1) expression in astrocytes. (A) Immunolabeling for SUR1 showed sparse immunoreactivity in the control
specimen (CTR) vs. widespread expression in a GFAP-positive specimen from contusion-TBI. (B) Double immunolabeling for SUR1
(red) and GFAP (green) showed astrocyte expression of SUR1; merged images confirm co-localization (yellow); in situ hybridization of
the same tissue section for Abcc8 messenger RNA showed positive signal co-localized with GFAP-positive, SUR1-expressing astro-
cytes; arrowheads point to cells with all three signals. (C) Three adjacent tissue sections from a GFAP-positive specimen im-
munolabeled using three different anti-SUR1 antibodies: our custom polyclonal antibody26 (ab1), a monoclonal antibody (S289-16;
Novus Biologicals; ab2), and a commercial polyclonal antibody (sc-5789; Santa Cruz Biotechnology; ab3): Note comparable labeling
by all three antibodies of stellate-shaped cells with good signal-to-noise ratio and minimal background labeling (case #2, 11 days post-
TBI; case #5, 1 day post-TBI). (D) Quantification of SUR1, transient receptor potential cation channel subfamily M member 4
(TRPM4), and KIR6.2 expression in GFAP-positive astrocytes in TBI specimens (red) vs. controls (black); quantification performed
based on GFAP-defined region of interest; scatterplots as well as box plots are shown; each symbol is from a different case; box plot
symbols: small box, mean; ––, median; large box, 25th and 75th percentile; · , 1st and 99th percentile; -, max and min: Note that in
controls, GFAP-positive astrocytes expressed minimal channel subunits, whereas all three channel subunits were overexpressed in
GFAP-positive astrocytes in contusion-TBI specimens; **p < 0.01. The findings illustrated are representative of all GFAP-positive
specimens from eight cases of human contusion-TBI.
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cells (Fig. 7D). SUR1 immunolabeling of the GFAP-negative core
did not show any stellate-shaped cells. By contrast, SUR1 im-
munolabeling of the GFAP-positive penumbra showed numerous
stellate-shaped cells, with these cells being the predominant cell-
type (Fig. 7D).
In core tissues, double immunolabeling with RECA and SUR1
or TRPM4 or KIR6.2 showed microvascular expression of SUR1
and TRPM4, but no convincing evidence of KIR6.2 (Fig. 8A-C).
Double immunolabeling of core tissues showed that SUR1 and
TRPM4 were co-localized in microvessels (Fig. 8D).
FIG. 5. Glial fibrillary acidic protein (GFAP)–positive specimens from human contusion– traumatic brain injury (TBI) exhibit
transient receptor potential cation channel subfamily M member 4 (TRPM4) expression in astrocytes. (A) Immunolabeling for TRPM4
showed sparse immunoreactivity in the control specimen (CTR) vs. widespread expression in a GFAP-positive specimen from
contusion-TBI (TBI). (B) Double immunolabeling for GFAP (red) and TRPM4 (green) showed astrocyte expression of TRPM4; merged
images confirms co-localization (yellow); in situ hybridization of the same tissue section for Trpm4 messenger RNA showed positive
signal co-localized with GFAP-positive, TRPM4-expressing astrocytes; arrowheads point to stellate-shaped cells with all three signals;
asterisk denotes GFAP-negative small round cell with TRPM4 protein and mRNA. (C) Double immunolabeling showing sulfonylurea
receptor 1 (SUR1; red) and TRPM4 (green) co-localization in perivascular astrocytes; merged images also shown (yellow). (D)
ImmunoFRET for SUR1 (red) and TRPM4 (magenta) shows co-assembly of SUR1-TRPM4 heteromers (yellow pseudocolor) in
astrocytes. The findings illustrated are representative of all GFAP-positive specimens from eight cases of human contusion-TBI. (case
#2, 11 days post-TBI; case #5, 1 day post-TBI)
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In core tissues, double immunolabeling with CD68 and SUR1 or
TRPM4 or KIR6.2 showed that microglia/macrophages accounted
for most of the small round cells, and that these cells expressed all
three channel subunits (Fig. 8E-G).
In the penumbra, double immunolabeling with GFAP and SUR1
or TRPM4 or KIR6.2 showed that astrocytes expressed all three
channel subunits (Fig. 9A-C). Quantification using GFAP as the
region of interest confirmed that SUR1, TRPM4 and KIR6.2 were
significantly upregulated in penumbral astrocytes post-TBI (Fig. 9G).
Double immunolabeling showed that SUR1 and TRPM4, SUR1 and
KIR6.2, as well as TRPM4 and KIR6.2 all co-localized in astrocytes
(Fig. 9D-F).
Glibenclamide and HPC
In the rat model, quantification of the hemorrhagic lesion area at
baseline (15 min) versus 24 h was used to gauge HPC. At baseline,
the hemorrhagic lesion area, reflecting the primary hemorrhage,
was small, whereas by 24 h, the hemorrhagic lesion area had grown
significantly (Fig. 10), reflecting the fact that the primary
FIG. 6. Glial fibrillary acidic protein (GFAP)–positive specimens from human contusion- traumatic brain injury (TBI) exhibit KIR6.2
expression in astrocytes. (A) Immunolabeling for KIR6.2 showed sparse immunoreactivity in the control specimen (CTR) vs. wide-
spread expression in a GFAP-positive specimen from contusion-TBI. (B) Double immunolabeling for GFAP (red) and KIR6.2 (green)
showed astrocyte expression of KIR6.2; merged images confirm co-localization (yellow); in situ hybridization of the same tissue section
for Kcnj11 messenger RNA showed positive signal co-localized with GFAP-positive, KIR6.2-expressing astrocytes; arrowheads point to
cells with all three signals. (C) Double immunolabeling showed that KIR6.2 (red) and sulfonylurea receptor 1 (SUR1; green) were co-
localized (yellow) in astrocytes. (D) ImmunoFRET for SUR1 (magenta) and KIR6.2 (red) showed co-assembly of SUR1-KIR6.2
heteromers (yellow pseudocolor) in astrocytes. (E) Double immunolabeling showed that KIR6.2 (green) and transient receptor potential
cation channel subfamily M member 4 (TRPM4) (red) were co-localized in astrocytes. The findings illustrated are representative of all
GFAP-positive specimens from eight cases of human contusion-TBI. (case #2, 11 days post-TBI; case #5, 1 day post-TBI)
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hemorrhage had undergone HPC.4 Images of the hemorrhages at
24 h confirmed that the increase in blood was not due to an increase
in bleeding from a point source, but was dispersed throughout
the tissues, consistent with hemorrhagic transformation of brain
(Fig. 10B). Measurements of hemispheric volume showed that
hemispheric swelling was commensurate with hemorrhagic lesion
area (Fig. 10D). Glibenclamide treatment initiated within 15 min
after trauma yielded a hemorrhagic lesion area at 24 h that was
significantly less than in vehicle-treated animals, reflecting a re-
duction in mean HPC by *58%. Similarly, glibenclamide treat-
ment was associated with hemispheric swelling at 24 h that was
significantly less than in vehicle-treated animals, with a reduction
in mean swelling of *66%.
AS-ODN and HPC
We used AS-ODNs to assess the functional role of the three
channel subunits in HPC. Circulating intravascular oligonucleotides
normally are excluded from the brain parenchyma by the intact
blood–brain barrier (BBB),46 but TBI causes BBB disruption47 that
enables delivery of circulating oligonucleotides to brain cells.
Moreover, following central nervous system (CNS) trauma, AS-
ODNs may be selectively taken up by activated endothelium.39,48
Within 15 min of trauma, rats were administered intravenous
AS-ODNs directed against Abcc8, Trpm4, or Kir6.2 mRNA. The
hemorrhagic lesion areas in controls for the three treatments were
not significantly different. Compared with controls, anti-Abcc8 and
FIG. 7. Sulfonylurea receptor 1 (SUR1) expression in rat contusion- traumatic brain injury (TBI). (A, B) Coronal image of contusion
(A) and coronal section immunolabeled for glial fibrillary acidic protein (GFAP; red) and stained for TUNEL (green; B), showing that
the hemorrhagic core is largely devoid of GFAP immunoreactivity, but shows widespread TUNEL labeling; the white line in (A) depicts
the output of the algorithm-based segmentation protocol used to identify the hemorrhagic lesion area (see Methods). (C, D) Quanti-
fication of total SUR1 expression in core (red) vs. penumbra (blue) as a function of time post-contusion-TBI; five rats per time-point; the
labels ‘‘microvessels,’’ ‘‘astrocytes,’’ and ‘‘macrophages’’ in (C) are based on high magnification views (D), showing that: 1) early in
the core, SUR1 is most prominent in elongated structures consistent with microvessels; 2) later in the core, SUR1 is most prominent in
small round cells; and 3) at all times in the penumbra, SUR1 is most prominent in stellate cells consistent with astrocytes.
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anti-Trpm4 AS-ODNs significantly reduced hemorrhagic lesion
areas at 24 h, while values for the two treatments were not signif-
icantly different from each other (Fig. 11). Assuming baseline
values comparable to those above, mean HPC was reduced *70%
and *92% by anti-Abcc8 and anti-Trpm4 AS-ODNs, respectively.
Similarly, AS-ODN treatment was associated with hemispheric
swelling at 24 h that was significantly less than in controls (Fig. 11),
with reductions in mean swelling of *58% and *70% by anti-
Abcc8 and anti-Trpm4 AS-ODNs, respectively. By contrast,
following administration of anti-Kir6.2 AS-ODN, hemorrhagic
lesion area and hemispheric swelling at 24 h were not significantly
different compared with controls (Fig. 11).
FIG. 8. Glial fibrillary acidic protein (GFAP)–negative specimens from rat contusion–traumatic brain injury (TBI) exhibit sulfonylurea
receptor 1 (SUR1) expression in microvessels and microglia/macrophages. (A-C) Double immunolabeling for rat endothelial cell antigen
(RECA) (green) and SUR1 (A) or transient receptor potential cation channel subfamily M member 4 (TRPM4) (B) or KIR6.2 (C) at 24 h post-TBI
showed expression of SUR1 and TRPM4 in microvessels; merged images are shown in the right panels (yellow). (D) Double immunolabeling for
SUR1 (green) and TRPM4 (red) at 24 h post-TBI shows co-localization in microvessels. (E-G) Double immunolabeling for CD68 (green) and
SUR1 (E) or TRPM4 (F) or KIR6.2 (G) at 72 h post-TBI showed expression of SUR1, TRPM4, and KIR6.2 in microglia/macrophages; merged
images are also shown. The findings illustrated are representative of five specimens from rat contusion-TBI with GFAP-negative core.
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Discussion
There are two major findings in the present report. First, indi-
vidual subunits and heteromers of SUR1-TRPM4 and KATP
(SUR1-KIR6.2) channels were upregulated after human TBI,
confirming and expanding on recent reports on SUR1 and KIR6.2
expression in human TBI,13,28 and recapitulating observations on
SUR1 and TRPM4 in animal models of contusion-TBI.4,12,27
Second, our data with AS-ODNs in the rat contusion model showed
that SUR1-TRPM4, not KATP (SUR1-KIR6.2), accounts best for
post-contusion HPC. Overall, our data support the hypotheses that
SUR1-TRPM4 plays a crucial role in contusion-TBI, and that a
primary target of glibenclamide in TBI is SUR1-TRPM4.
Channel subunit expression in human contusions
Dichotomizing tissues as being GFAP-positive versus GFAP-
negative facilitated our investigation of channel subunit expression
in various cell types. This classification is justified by observations
both here and previously that GFAP expression is reduced or absent
in the core of ischemic and contusion injuries,43–45 whereas it is
upregulated in surrounding penumbral regions. Equating GFAP
immunoreactivity with core versus penumbra may be a broad
generalization, but it was useful for predicting the cell types and
patterns of SUR1 expression.
In GFAP-negative core tissues, SUR1 was upregulated most
prominently in two cell types, microvascular endothelium and
FIG. 9. Glial fibrillary acidic protein (GFAP)–positive specimens from rat contusion– traumatic brain injury (TBI) exhibit sulfo-
nylurea receptor 1 (SUR1) expression in astrocytes. (A-C) Double immunolabeling for GFAP (green) and SUR1 (A) or transient
receptor potential cation channel subfamily M member 4 (TRPM4) (B) or KIR6.2 (C) showed expression of all three channel subunits in
astrocytes; merged images are shown in the right panels (yellow). (D-F) Double immunolabeling for SUR1 and TRPM4 (D), SUR1 and
KIR6.2 (E), and TRPM4 and KIR6.2 (F), shows co-localization in astrocytes; merged images are shown in the right panels (yellow). (G)
Expression of SUR1, TRPM4 and KIR6.2 in GFAP-positive astrocytes in TBI specimens (red) vs. controls (black); quantification
performed based on GFAP-defined region of interest; scatterplots as well as box plots are shown; box plot symbols are the same as in
Figure 4: Note that in controls, GFAP-positive astrocytes expressed minimal channel subunits, whereas all three channel subunits were
expressed in GFAP-positive astrocytes in contusion-TBI specimens; **p < 0.01.
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CD68-positive microglia/macrophages. By contrast, in GFAP-
positive penumbral tissues, SUR1 was upregulated predominantly
in astrocytes. In specimens characterized using FRET, we found
evidence of SUR1-TRPM4 heteromers in microvascular endothe-
lium, whereas both SUR1-TRPM4 and SUR1-KIR6.2 heteromers
were identified in astrocytes. Cortical neurons also express SUR1
as part of KATP channels, and SUR1 in neurons previously was
reported to be increased in human TBI specimens,13 but here, we
did not quantify channel subunit expression in neurons.
Overall, our findings in human TBI accord with observations on
SUR1 in human TBI by Martinez-Valverde and colleagues,13 and
they accord with findings on SUR1 in TBI rat models reported here
and previously.4,12 Also, our findings on KIR6.2 accord with pre-
vious observations in human TBI by Castro and colleagues,28 who
first reported upregulation of KIR6.2, predominantly in astrocytes.
The present study is the first to report on TRPM4 in the human brain
after TBI, and our findings are in accord with those reported in a
diffuse-TBI rat model.27
KATP
KATP channels are activated by processes associated with energy
deprivation (e.g., a fall in the ATP/ADP ratio). Work investigating the
function of neuronal KATP channels under pathological conditions has
focused primarily on their role in hypoxia or excitotoxicity.49–51
These studies showed that KATP channels mediate neuronal hy-
perpolarization, which counteracts anoxic/ischemic depolarization,
and thereby reduces neuronal death. In accord with this, KIR6.2-null
mice are vulnerable to brain hypoxia, and exhibit a reduced
threshold for hypoxia-induced generalized seizures,52,53 while
KIR6.2-overexpressing mice are protected.54
Whereas constitutive KIR6.2 expression by neurons is estab-
lished, KIR6.2 expression in glial cells in the normal brain is
controversial, or may depend on location. Dunn-Meynell and col-
leagues55 reported that while various neurons in rat brain express
KIR6.2 mRNA, neither astrocytes nor oligodendrocytes express
KIR6.2 mRNA. Conversely, Zhou and colleagues56 showed that
glia in the rodent corpus callosum and cerebellar white matter (but
not cerebral cortex) weakly express KIR6.2. In the present study, as
well as in the report by Castro and colleagues,28 KIR6.2 was not
identified in astrocytes in control human cortex.
Conversely, several reports indicate that astrocytes normally ex-
press the closely related subunit KIR6.1.57,58 Moreover, recent data
indicate that in disease states, there may be a dramatic increase in
KIR6.2 expression in reactive protoplasmic and fibrous astrocytes,
whereas no such increase is observed for KIR6.1, a phenomenon that
was termed ‘‘aberrant expression of KIR6.2.’’59 In both the report by
Castro and colleagues28 as well as here, so-called aberrant expression
of KIR6.2 in reactive astrocytes was identified post-TBI. Although
questions may remain about constitutive expression of KIR6.2 in
FIG. 10. Glibenclamide reduces hemorrhagic progression of contusion (HPC). (A-C) Images of coronal sections of brains through the
epicenter, obtained in vehicle-treated animals 15 min after trauma (A) and 24 h after trauma (B), or in a glibenclamide-treated animal
24 h after trauma (C); the increase in area of brain exhibiting hemorrhagic transformation between 15 min and 24 h represents HPC. (D)
Quantification of hemorrhagic lesion area (above) or hemispheric swelling (below) in vehicle-treated animals 15 min after trauma
(black) and 24 h after trauma (red), or in glibenclamide-treated animals 24 h after trauma (green); 5 or 9 rats per group; box plot symbols
same as in Figure 4; **p < 0.01 with respect to 15 min; ##p < 0.01 with respect to 24 h controls.
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quiescent astrocytes, upregulation of KIR6.2 in cortical reactive as-
trocytes under pathological conditions seems certain.
In contrast to neurons and astrocytes, KATP channel subunits are
essentially undetectable in endothelium of normal brain micro-
vessels or endothelium of the basilar and middle cerebral arteries,
although smooth muscle cells of cerebral arteries express the var-
ious subunits.60,61 Vascular smooth muscle KATP channels mediate
vasodilation in response to hypoxia.62,63
The role of KATP in TBI, especially in penumbral astrocytes
where KIR6.2 is strongly upregulated, remains unknown. Our
FIG. 11. AS-ODN targeting Abcc8 and Trpm4, but not Kcnj11, reduces hemorrhagic progression of contusion (HPC). (A) Images of
coronal sections of brains through the epicenter, obtained 24 h after trauma in animals administered control-ODN (CTR), Abcc8-ODN,
Trpm4-ODN or Kcnj11-ODN, as indicated; arrowheads point to distinct petechial hemorrhages. (B) Quantification of hemorrhagic
lesion area (above) or hemispheric swelling (below), in control-ODN-treated animals 24 h after trauma (red), and in Abcc8- or Trpm4- or
Kcnj11-ODN-treated animals 24 h after trauma (blue); control-ODN was either scrambled (Scr) or sense (SE) ODN, as indicated; 7–12
rats per group; box plot symbols same as in Figure 4; **p < 0.01 with respect to control; analysis of variance revealed no statistically
significant difference between the three controls, or between Kcnj11-ODN-treated animals and controls.
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experiments with AS-ODN targeting KIR6.2 did not identify a role
for KIR6.2, and by inference for KATP, in brain swelling or HPC.
Given the prominent expression of KATP in penumbral astrocytes
post-TBI, we infer that astrocytes do not play a substantive role in
HPC. Although we cannot rule out a problem with AS-ODN entry
into astrocytes in vivo in our experiments, we note that the same
AS-ODN was shown to be effective in downregulating KIR6.2 in
basal ganglia neurons in vivo.40 Importantly, our negative data with
anti-KIR6.2 AS-ODN do not imply that KIR6.2 upregulation in
reactive astrocytes is without function, only that our experiments
did not identify that function in TBI. Future work will examine this
important question more carefully.
SUR1-TRPM4
In animal models of contusion-TBI, blockade of SUR1 with
glibenclamide reduces capillary fragmentation in the penumbra,
which is the immediate cause of HPC.4 In our previous study, we
quantified HPC based on spectrophotometric analysis of tissue
hemoglobin, and found that the hemoglobin content increased *2-
fold between baseline and 24 h, and that this increase was blunted
by *90% by glibenclamide.4 In the present study, we quantified
HPC based on the area of hemorrhagic brain visible on single
coronal images for each rat, and found that the hemorrhagic area
increased *2-fold between baseline and 24 h, and that this increase
was blunted by *50% by glibenclamide. Independent studies in rat
and mouse models of contusion-TBI that used either MRI14 or
tissue hemoglobin15 reported that glibenclamide reduced hemorrhagic
lesion volumes by*50%. A study in humans with contusion-TBI that
used volumetric analysis of CT scans found that glibenclamide re-
duced hemorrhagic lesion volumes by *80%.22 This broad concor-
dance on the robust effect of glibenclamide across independent
laboratories and across different species underscores the important
role of SUR1 in HPC.
Glibenclamide is a sulfonylurea drug that targets sulfonylurea
receptors, of which three are known: SUR1, SUR2A, and SUR2B.
Of these, glibenclamide exhibits the highest potency at SUR1.64
Here, we found that the effects of glibenclamide on HPC and brain
swelling were closely mimicked by anti-SUR1 AS-ODN, which
largely eliminates involvement of SUR2A and SUR2B in HPC
after contusion-TBI, and is consistent with glibenclamide acting via
SUR1, not via some off-target effect.
We showed that the effects of blocking SUR1 are replicated
using AS-ODN directed against Trpm4. These findings establish,
for the first time, that SUR1-TRPM4 is a dominant molecular
mechanism responsible for HPC. Notably, previous work in non-
TBI models also showed that suppression of SUR1 and TRPM4
results in an essentially identical post-injury phenotype. In a contu-
sion spinal cord injury model, genetic suppression of either subunit is
similarly effective at preventing ‘‘progressive hemorrhagic necro-
sis,’’39,48,65 a process of hemorrhagic lesion expansion in SCI that is
similar to HPC in TBI. In experimental allergic encephalomyelitis,
genetic suppression of either subunit is similarly effective at reducing
inflammation and disease progression.66 In activated microglia
in vitro, pharmacological inhibition of either subunit is similarly
effective at reducing transcription of nitric oxide synthase 2.67 In
activated astrocytes in vitro, pharmacological inhibition of either
subunit is similarly effective at reducing cell swelling.68 Thus, in
diverse CNS injury scenarios, the SUR1-TRPM4 channel plays a
critical role in pathogenesis, with blockade or inhibition of either
subunit yielding a similar favorable post-injury phenotype.
Co-expression of KATP and SUR1-TRPM4
Some cells, including astrocytes and microglia/macrophages,
were found to express both KATP and SUR1-TRPM4 channels. As
plasmalemmal channels, these two channels have opposite effects
on membrane polarization—upon activation, KATP channels me-
diate K+ efflux and cell hyperpolarization, whereas SUR1-TRPM4
channels mediate Na+ influx and cell depolarization. These oppo-
site functions may not conflict, however, since the two channels are
regulated differently by intracellular ATP and calcium, which in-
teract with the pore-forming subunit, not SUR1. KATP (SUR1-
KIR6.2) is inhibited by ATP with an EC50 *18 lM, and the in-
hibitory action of ATP is counteracted by ADP,69,70 whereas
SUR1-TRPM4 is inhibited by ATP with an EC50 0.8 lM, with no
effect of ADP.71 Moreover, of the two subunits, only TRPM4 is
sensitive to intracellular calcium/calmodulin.26,71 Thus, although
both have the same SUR1 regulatory subunit, independent regu-
lation of the two channels via the different pore-forming subunits is
likely. Other cells also are known to express SUR1, KIR6.2, and
TRPM4 simultaneously, including pancreatic b cells72 and neurons
of the arcuate nucleus.73 Notably, in pancreatic b cells, KATP and
TRPM4 function together to regulate insulin secretion,72,74 illus-
trating co-operative, not mutually opposed, functions. Further
study is needed to determine the subcellular localization and to
identify the complex functional interactions served by co-
expression of KATP and SUR1-TRPM4 in reactive astrocytes and
microglia/macrophages post-TBI.
Brain swelling
In TBI, brain swelling is directly responsible for major morbidity
and death.10,11 In TBI, more so than in ischemia, it is important to
distinguish between ‘‘brain swelling’’ and ‘‘brain edema,’’ two terms
that are occasionally conflated but are not equivalent. Whereas
edema contributes to brain swelling, edema is only one of several
distinct space-occupying components responsible for swelling. Brain
swelling arises from the combined space-occupying effects of ex-
travasated blood, extracellular edema fluid, cellular swelling, vas-
cular engorgement, and, possibly, hydrocephalus. Extravasated
blood from both the initial contusion and from HPC contributes in
a major way to brain swelling. Extracellular edema fluid, which
develops later via two distinct mechanisms (see below), is another
important contributor. Cellular swelling, especially of astrocytes,
may be a larger contributor to brain swelling than is usually ac-
knowledged.27,75 Post-traumatic vascular engorgement or hyper-
emia, which is attributed to vasoparalysis or venous outflow
obstruction, also may contribute significantly to brain swelling.76,77
Some of these processes develop rapidly, while others worsen pro-
gressively over days. All have different underlying mechanisms, and
while some may be inhibitable, at least in principal, others are not.
In the present study, extravasated blood was found to be a major
contributor to brain swelling. The finding that glibenclamide, anti-
SUR1 AS-ODN and anti-TRPM4 AS-ODN reduced brain swelling
at 24 h by approximately half (Fig. 10 and Fig. 11) is best attributed
to a treatment-related reduction in secondary hemorrhage from
HPC, which was of a similar magnitude. At 24 h, extravasated
blood seems to be the dominant factor responsible for brain
swelling in this TBI model. This finding accords with the obser-
vation in humans that midline shift, a measure of hemispheric
swelling, and hematoma volume are nearly co-linear.10 Notably,
pharmacological inhibition of SUR1 was shown recently in a hu-
man clinical trial to reduce HPC after TBI.22
1076 GERZANICH ET AL.
In TBI, edema forms via two distinct mechanisms, with the
distinction based on the origin of the osmotically active solute,
either intracontusional or intravascular. The intracontusional
component was characterized by Katayama and colleagues,78 who
showed that hemorrhagic/necrotic lesions in BCs have very high
osmolarity. The increase in osmotic pressure is due to metabolic
production of osmoles or the release of idiogenic osmoles from
necrotic tissues.79 The high osmolarity of the hyperosmolar core
acts as a powerful force that attracts water from the perilesional
brain through a compromised BBB. In this case, the causative os-
molytes originate from within the contusion. This component of
edema can be reduced by intravascular osmotherapies, which
counteract the transport of water from the vascular compartment
into the tissues, but because water flux from the vascular com-
partment cannot be specifically blocked, this component is not
amenable to targeted pharmacological inhibition.
The second component of edema is driven by osmotically active
solutes, in this case ions and proteins, that are transported from
the vascular compartment into the injured brain, to form ionic
and vasogenic edema. Involvement of endothelial transporters/
co-transporters such as SUR1-TRPM4 in this process suggests that
this component may be subject to pharmacological inhibition. In a
rat contusion-TBI model, with an increase in brain water from 78.5
to 80.8%, Zweckberger and colleagues14 reported that glib-
enclamide decreased excess water down to 80.5%, or by 15%. In a
mouse contusion-TBI model complicated by hypotension, with an
increase in brain water from 78.3 to 80.4%, Jha and colleagues17
reported that glibenclamide did not reduce ipsilateral excess water,
but that contralateral excess water, which was increased from 78.3
to 78.6%, was eliminated by the drug. In a mouse contusion-TBI
model, Xu and colleagues15 reported that glibenclamide reduced
Evans blue extravasation by 35%. Glibenclamide was shown re-
cently in a human clinical trial to reduce brain swelling from edema
after ischemic stroke,21 but a comparable effect on edema in human
TBI remains to be examined. In the present study, our experiments
with AS-ODNs were designed explicitly to address HPC and its
role in hemispheric swelling, not the subsequent development of
edema. Future studies will examine the effects of AS-ODNs on
edema formation in a rat contusion-TBI model.
Conclusion
In humans and rats, contusion-TBI is accompanied by upregu-
lation of SUR1-TRPM4 in endothelium, astrocytes and microglia/
macrophages, and of KATP (SUR1-KIR6.2) in astrocytes and mi-
croglia/macrophages, with cell-type specific expression being dif-
ferent in the lesion core versus the penumbra. In vivo experiments
with AS-ODNs show that SUR1-TRPM4 plays a critical role in
HPC and in early brain swelling, whereas a role for KATP in TBI has
yet to be identified.
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